$XOMA
XOMA Royalty Corp

2023 Q3 Form 10-Q Financial Statement

#000155837023013756 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $830.0K $1.658M
YoY Change 84.04% 68.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.370M $5.777M
YoY Change 32.87% 1.17%
% of Gross Profit
Research & Development $25.00K $39.00K
YoY Change -13.79% -2.5%
% of Gross Profit
Depreciation & Amortization $220.0K $224.0K
YoY Change 5400.0% 22300.0%
% of Gross Profit
Operating Expenses $6.617M $7.615M
YoY Change 37.2% 32.43%
Operating Profit -$5.787M -$5.957M
YoY Change 32.37% 24.96%
Interest Expense $280.0K $557.0K
YoY Change 44.33% 860.34%
% of Operating Profit
Other Income/Expense, Net $278.0K $557.0K
YoY Change 43.3% 474.23%
Pretax Income -$5.510M -$5.400M
YoY Change 31.88% 15.63%
Income Tax
% Of Pretax Income
Net Earnings -$5.509M -$5.400M
YoY Change 31.86% 15.63%
Net Earnings / Revenue -663.73% -325.69%
Basic Earnings Per Share -$0.60 -$0.59
Diluted Earnings Per Share -$0.60 -$0.59
COMMON SHARES
Basic Shares Outstanding 11.47M 11.46M
Diluted Shares Outstanding 11.47K 11.47K

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.70M $31.77M
YoY Change -57.19% -62.05%
Cash & Equivalents $33.50M $31.40M
Short-Term Investments $200.0K $320.0K
Other Short-Term Assets $800.0K $799.0K
YoY Change -19.76% -23.98%
Inventory
Prepaid Expenses
Receivables $0.00 $901.0K
Other Receivables $0.00 $4.958M
Total Short-Term Assets $34.51M $38.42M
YoY Change -56.73% -55.97%
LONG-TERM ASSETS
Property, Plant & Equipment $5.000K $5.000K
YoY Change -37.5% -50.0%
Goodwill
YoY Change
Intangibles $14.48M $14.70M
YoY Change
Long-Term Investments
YoY Change
Other Assets $411.0K $283.0K
YoY Change 58.08% 8.85%
Total Long-Term Assets $89.59M $87.24M
YoY Change 34.94% 30.28%
TOTAL ASSETS
Total Short-Term Assets $34.51M $38.42M
Total Long-Term Assets $89.59M $87.24M
Total Assets $124.1M $125.7M
YoY Change -15.08% -18.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $728.0K $740.0K
YoY Change -26.09% -35.82%
Accrued Expenses $2.200M $1.950M
YoY Change 70.15% 68.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.33M $7.087M
YoY Change 90.49% -15.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.800M $8.450M
YoY Change -24.86% -22.06%
Total Long-Term Liabilities $7.800M $8.450M
YoY Change -24.86% -22.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.33M $7.087M
Total Long-Term Liabilities $7.800M $8.450M
Total Liabilities $18.13M $15.54M
YoY Change 14.7% -19.36%
SHAREHOLDERS EQUITY
Retained Earnings -$1.203B -$1.198B
YoY Change 2.27% 2.16%
Common Stock $86.00K $86.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.0M $110.1M
YoY Change
Total Liabilities & Shareholders Equity $124.1M $125.7M
YoY Change -15.08% -18.52%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.509M -$5.400M
YoY Change 31.86% 15.63%
Depreciation, Depletion And Amortization $220.0K $224.0K
YoY Change 5400.0% 22300.0%
Cash From Operating Activities -$2.100M -$7.208M
YoY Change -42.67% 66.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.500M -$4.482M
YoY Change 21053.85%
Cash From Investing Activities $5.500M -$4.482M
YoY Change 21053.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.370M -1.165M
YoY Change 8.73% 2.73%
NET CHANGE
Cash From Operating Activities -2.100M -7.208M
Cash From Investing Activities 5.500M -4.482M
Cash From Financing Activities -1.370M -1.165M
Net Change In Cash 2.030M -12.85M
YoY Change -141.45% 135.83%
FREE CASH FLOW
Cash From Operating Activities -$2.100M -$7.208M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0000791908
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39801
dei Entity Registrant Name
EntityRegistrantName
XOMA Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2154066
dei Entity Address Address Line1
EntityAddressAddressLine1
2200 Powell Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 310
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
204-7200
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11472808
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31445000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57826000
CY2023Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
320000
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
335000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
901000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1000
CY2023Q2 xoma Rights Receivable Current
RightsReceivableCurrent
4958000
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2366000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
799000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
725000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
38423000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
61253000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29000
CY2023Q2 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
72232000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63683000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14701000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15150000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
283000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
260000
CY2023Q2 us-gaap Assets
Assets
125661000
CY2022Q4 us-gaap Assets
Assets
140382000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
740000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
524000
CY2023Q2 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1933000
CY2022Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2918000
CY2023Q2 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
1000000
CY2022Q4 xoma Contingent Consideration Under Purchase Agreements
ContingentConsiderationUnderPurchaseAgreements
75000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000
CY2023Q2 us-gaap Deferred Income Current
DeferredIncomeCurrent
2029000
CY2022Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
1899000
CY2023Q2 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2022Q4 xoma Accrued Preferred Stock Dividend Current
AccruedPreferredStockDividendCurrent
1368000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7087000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6818000
CY2023Q2 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
8450000
CY2022Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
9550000
CY2023Q2 us-gaap Liabilities
Liabilities
15537000
CY2022Q4 us-gaap Liabilities
Liabilities
16368000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.05
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0075
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
277333332
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11472808
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11472808
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11454025
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11454025
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
86000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
86000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1307594000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1306271000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1197605000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1182392000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110124000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
124014000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125661000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140382000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
525000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1125000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3275000
CY2023Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
533000
CY2022Q2 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
458000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
970000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
815000
CY2023Q2 us-gaap Revenues
Revenues
1658000
CY2022Q2 us-gaap Revenues
Revenues
983000
us-gaap Revenues
Revenues
2095000
us-gaap Revenues
Revenues
4090000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5777000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5710000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11973000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10826000
CY2023Q2 xoma Impairment Of Long Term Rights Receivable Non Current
ImpairmentOfLongTermRightsReceivableNonCurrent
1575000
xoma Impairment Of Long Term Rights Receivable Non Current
ImpairmentOfLongTermRightsReceivableNonCurrent
1575000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
4132000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
224000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
449000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7615000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
5750000
us-gaap Operating Expenses
OperatingExpenses
18222000
us-gaap Operating Expenses
OperatingExpenses
10922000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5957000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4767000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16127000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6832000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
557000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
97000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
914000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-118000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5400000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5400000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4670000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4670000
us-gaap Net Income Loss
NetIncomeLoss
-15213000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15213000
us-gaap Net Income Loss
NetIncomeLoss
-6950000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6950000
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1368000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2736000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2736000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6768000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6768000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6038000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6038000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17949000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17949000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9686000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9686000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11466
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11466
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11421
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11421
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11463
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11376
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11376
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
124014000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
123000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1570000
CY2023Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9813000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
114526000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
50000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2163000
CY2023Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5400000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
110124000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141876000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
633000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
85000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
978000
CY2022Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2280000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
139924000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
189000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
45000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
836000
CY2022Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
1368000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4670000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
134956000
us-gaap Profit Loss
ProfitLoss
-15213000
us-gaap Profit Loss
ProfitLoss
-6950000
us-gaap Share Based Compensation
ShareBasedCompensation
3733000
us-gaap Share Based Compensation
ShareBasedCompensation
1815000
xoma Impairment Of Long Term Rights Receivable Non Current
ImpairmentOfLongTermRightsReceivableNonCurrent
1575000
xoma Changes In Estimated Fair Value Of Contingent Consideration
ChangesInEstimatedFairValueOfContingentConsideration
75000
xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
123000
xoma Defined Contribution Plan Issuance Of Common Stock For Services Or Claims
DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
85000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
449000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
2000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
3000
xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-97000
xoma Operating Lease Payments Non Cash
OperatingLeasePaymentsNonCash
-84000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-15000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-251000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
900000
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-204000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
97000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
398000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-769000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
582000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-91000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-102000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-96000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-970000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-815000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12132000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5326000
xoma Payment Of Consideration Under Agreements Investing Activities
PaymentOfConsiderationUnderAgreementsInvestingActivities
14650000
xoma Payment Of Consideration Under Agreements Investing Activities
PaymentOfConsiderationUnderAgreementsInvestingActivities
5000000
xoma Receipts Under Agreements Investing Activities
ReceiptsUnderAgreementsInvestingActivities
2934000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11716000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000000
us-gaap Payments Of Dividends
PaymentsOfDividends
2736000
us-gaap Payments Of Dividends
PaymentsOfDividends
2736000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
208000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1905000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1038000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2533000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1869000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26381000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12195000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57826000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
95377000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31445000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83182000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
95000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
85000
CY2023Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
CY2022Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1368000
xoma Estimated Fair Value Of Contingent Consideration Under Asset Acquisition
EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition
1000000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company’s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company’s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of June 30, 2023, the Company had cash and cash equivalents of $31.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company’s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.</p>
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company’s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p>
CY2023Q2 us-gaap Cash
Cash
1300000
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30100000
CY2022Q4 us-gaap Cash
Cash
27500000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
30300000
CY2023Q2 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
978000
CY2022Q4 xoma Accrued Salaries And Employee Benefits Current
AccruedSalariesAndEmployeeBenefitsCurrent
1449000
CY2023Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
604000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
562000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
331000
CY2022Q4 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P17Y
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
867000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2023Q2 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1933000
CY2022Q4 xoma Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
2918000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended June 30, 2023, two partners represented 66% and 32% of total revenues. For the six months ended June 30, 2023, two partners represented 53% and 46% of total revenues. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of June 30, 2023. There were no trade receivables, net balance as of December 31, 2022.</p>
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
0
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15247000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
546000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14701000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15247000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
97000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15150000
CY2023Q2 us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P16Y4M24D
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
448000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
897000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
897000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
897000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
897000
CY2023Q2 xoma Finite Lived Intangible Asset Expected Amortization Through Year Five
FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive
4036000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5400000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4670000
us-gaap Net Income Loss
NetIncomeLoss
-15213000
us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6768000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6768000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6038000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6038000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17949000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17949000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9686000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9686000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11466
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11466
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11421
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11421
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11463
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11376
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11376
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6728000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5898000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6643000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5822000
CY2021Q2 xoma Number Of Arbitration Proceedings Initiated
NumberOfArbitrationProceedingsInitiated
1
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
4100000
CY2023Q2 xoma Rights Receivable Current
RightsReceivableCurrent
5000000.0
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2400000
CY2023Q2 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
72200000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63700000
CY2022Q4 xoma Rights Receivable Current
RightsReceivableCurrent
2366000
CY2022Q4 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
63683000
CY2023Q2 xoma Rights Receivable Current
RightsReceivableCurrent
4958000
CY2023Q2 xoma Long Term Rights Receivable Non Current
LongTermRightsReceivableNonCurrent
72232000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
34000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
51000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
44000
us-gaap Operating Lease Cost
OperatingLeaseCost
99000
us-gaap Operating Lease Cost
OperatingLeaseCost
88000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
7000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
2000
us-gaap Variable Lease Cost
VariableLeaseCost
12000
us-gaap Variable Lease Cost
VariableLeaseCost
5000
CY2023Q2 us-gaap Lease Cost
LeaseCost
58000
CY2022Q2 us-gaap Lease Cost
LeaseCost
46000
us-gaap Lease Cost
LeaseCost
111000
us-gaap Lease Cost
LeaseCost
93000
us-gaap Operating Lease Payments
OperatingLeasePayments
104000
us-gaap Operating Lease Payments
OperatingLeasePayments
101000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y2M1D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0551
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11177
CY2023Q2 xoma Contractual Obligation Estimated Milestone Payments
ContractualObligationEstimatedMilestonePayments
6300000
CY2023Q2 xoma Contractual Obligation Estimated Milestone Payments Number Of Products
ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
1
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2025542
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.24
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10804000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
796802
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
23.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8473
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
18.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
71123
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
36.36
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2742748
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M3D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11430000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1815920
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.30
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y5M8D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11296000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
18000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2100000
CY2023Q2 xoma Accrued Retention Bonus
AccruedRetentionBonus
300000
CY2022Q4 xoma Accrued Retention Bonus
AccruedRetentionBonus
100000
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5900000
CY2023Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2023Q2 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001558370-23-013756-index-headers.html Edgar Link pending
0001558370-23-013756-index.html Edgar Link pending
0001558370-23-013756.txt Edgar Link pending
0001558370-23-013756-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xoma-20230630.xsd Edgar Link pending
xoma-20230630x10q.htm Edgar Link pending
xoma-20230630xex10d3.htm Edgar Link pending
xoma-20230630xex10d4.htm Edgar Link pending
xoma-20230630xex31d1.htm Edgar Link pending
xoma-20230630xex31d2.htm Edgar Link pending
xoma-20230630xex32d1.htm Edgar Link pending
xoma-20230630_def.xml Edgar Link unprocessable
xoma-20230630_lab.xml Edgar Link unprocessable
xoma-20230630_pre.xml Edgar Link unprocessable
xoma-20230630x10q_htm.xml Edgar Link completed
xoma-20230630_cal.xml Edgar Link unprocessable